Related Experiment Video
Updated: Feb 28, 2026
Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
Published on: January 10, 2025
Counteractive Effects of Diarylpropionitrile on Testosterone-Induced Benign Prostatic Hyperplasia in Rats via
Ahmed Khalafa Ali1, Ahmed Rahmah Abu-Raghif2, Hayder Ridha-Salman3,4
1Department of Pharmacology, Al-Nahrain University College of Medicine, Baghdad, Iraq.
Background:
Benign prostatic hyperplasia is a common public health problem in aging men across the globe. Diarylpropionitrile, a selective estrogen receptor-beta agonist, favorably regulates cell proliferation and inflammation, two major hallmarks of benign prostatic hyperplasia pathology.
Objective:
This study aimed to explore the mitigative impact of diarylpropionitrile on testosterone-induced benign prostatic hyperplasia in rats.
Methods:
Forty male rats were randomly divided into four groups (n=10): a normal control group, a benign prostatic hyperplasia group, a finasteride-treated group, and a diarylpropionitrile-treated group. After 4 weeks of treatment, macroscopic and microscopic features of prostatic hyperplasia and androgenic, proliferative, angiogenic, apoptotic, and inflammatory biomarkers were assessed.
Results:
Testosterone administration significantly increased prostate weight, prostatic index, and hyperplasia scores. Both diarylpropionitrile and finasteride effectively ameliorated the benign prostatic hyperplasia lesions by reversing these changes. Both treatments significantly lowered elevated prostatic dihydrotestosterone, 5-αR2, β-catenin, and proliferating cell nuclear antigen levels, demonstrating a strong anti-proliferative effect. They also attenuated the increased pro-inflammatory cytokines interleukin-6, interleukin-27, and prostaglandin E2 and growth factors transforming growth factor beta and vascular endothelial growth factor. Furthermore, both agents inhibited testosterone-induced estrogen receptor-beta upregulation, counteracted peroxisome proliferator-activated receptor gamma tissue protein, and boosted the expression of the anti-apoptotic marker B-cell lymphoma 2.
Conclusions:
Diarylpropionitrile alleviates testosterone-induced benign prostatic hyperplasia in rats by modulating key pathways associated with cellular proliferation and inflammation. Diarylpropionitrile, as an estrogen receptor-beta agonist, represents a promising alternative for the benign prostatic hyperplasia treatment through multi-targeted mechanisms.
Related Concept Videos
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:23Antihypertensive Drugs: Vasodilators
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...